SARS-CoV-2 Synthetic RNA Fragments Guidance Sheet

Research Grade Test Material ID: 10169

Sample Description

Each unit of RGTM 10169 consists of two tubes each containing a unique synthetic RNA fragment from the SARS-CoV-2 genome. Each tube contains approximately 110 μ L of the material in a background of 5 ng/ μ L human Jurkat RNA (stored at -80 °C, BSL-1). The concentration is approximately 5 x 10⁶ copies/ μ L as estimated by multiple digital PCR assays (RT-dPCR). Table 1 below lists assay-specific concentration estimates as measured by RT-dPCR.




Figure 1. Schematic of RGTM 10169 synthetic RNA fragments

- Fragment 1: Total length: 3985 nt, Includes SARS-CoV-2 sequence: 25949-29698 of isolate USA-WA1/2020
- Fragment 2: Total length: 3790 nt, Includes SARS-CoV-2 sequence: 12409-15962 of isolate USA-WA1/2020

Purpose

- To aid in evaluation and development of new and existing RT-qPCR assays.
- To understand SARS-CoV-2 analytical assay performance with a synthetic RNA material.
- To calibrate RT-qPCR methods and to benchmark/compare other SARS-CoV-2 controls/materials.

Reply Date

Your feedback regarding use of this material will help us further test, develop, and improve the materials for future development. Please return your feedback survey by

August 31, 2020. After that date, please contact us using the information below to determine whether responses are still being collected and the material still stable.

How to Reply

A survey link will be provided on the RGTM 10169 resource page here: <u>https://www.nist.gov/programs-projects/sars-cov-2-research-grade-test-material</u>

NIST Contacts

Megan Cleveland Megan.Cleveland@nist.gov Peter Vallone Peter.Vallone@nist.gov

Storage

The material should be stored frozen at -80 °C.

Notice and Warnings

Please review the Safety Data Sheet provided with this material. The Safety Data Sheet can also be downloaded from: <u>https://www.nist.gov/programs-projects/sars-cov-2-research-grade-test-material</u>

Instructions for Use

Thaw the tube at room temperature. Once thawed, vortex briefly, centrifuge briefly and repeat. Note: multiple freeze thaws of the material may result in lower concentration estimates.

NIST Additional Information

Supplemental data are available at: https://github.com/usnistgov/RGTM10169

Table 1

Median concentration values (copies/microliter) as measured by RT-dPCR assays. Note: "Assay Name" is an internal designation used by NIST and not intended to align nor conflict with alternative assay naming conventions.

Fragment 1	Assay Name	Target Region	Median concentration
			(copies/microliter)
	China N	N gene	2.4E+06
	Japan	N gene	4.5E+06
	N1	N gene	2.2E+06
	N2	N gene	4.6E+06
	N3	N gene	4.5E+06
	Thai	N gene	1.9E+06
	Sarbeco E	E gene	5.4E+06

Fragment 2	Assay Name	Target Region	Median concentration
			(copies/microliter)
	China ORF1ab	ORF1ab	5.2E+06
	Pasteur 1	ORF1ab	5.3E+06
	Pasteur 2	ORF1ab	5.1E+06
	RdRp	ORF1ab	4.1E+05

Tables 2 and 3

RT-dPCR assay primers and information. The RT-dPCR assays were developed and optimized using primer and probe sequences from:

https://github.com/usnistgov/RGTM10169/blob/master/whoinhouseassays_June_25_202 0.pdf. Note: "Assay Name" is an internal designation used by NIST and not intended to align nor conflict with alternative assay naming conventions.

Table 2: Fragment 1

Assay	Assay	Primer and Probe Sequences	Alternate assay
Developer	Name	_	names
Centers for	China N	F- ggggaacttctcctgctagaat	Centers for Disease
Disease		P- ttgctgctgcttgacagatt	Control, China, novel
Control, China		R- cagacattttgctctcaagctg	coronavirus Target 2
National	Japan	F- aaattttggggaccaggaac	National Institute of
Institute of		P- atgtcgcgcattggcatgga	Infectious Diseases,
Infectious		R- tggcagctgtgtaggtcaac	Japan, NIID_2019-
Diseases,			nCoV_N
Japan			
United States	N1	F- gaccccaaaatcagcgaaat	United States Centers
Centers for		P- accccgcattacgtttggtggacc	for Disease Control,
Disease		R- tctggttactgccagttgaatctg	2019-nCoV N1
Control			
United States	N2	F- ttacaaacattggccgcaaa	United States Centers
Centers for		P- acaatttgcccccagcgcttcag	for Disease Control,
Disease		R- gcgcgacattccgaagaa	2019-nCoV N2
Control			
United States	N3	F- gggagccttgaatacaccaaaa	United States Centers
Centers for		P- aycacattggcacccgcaatcctg	for Disease Control,
Disease		R- tgtagcacgattgcagcattg	2019-nCoV N3
Control			

World Health	Sarbeco E	F- acaggtacgttaatagttaatagcgt	World Health
Organization		P- acactagccatccttactgcgcttcg	Organization, n-CoV
		R- atattgcagcagtacgcacaca	Sarbeco-E
Ministry of	Thai	F- cgtttggtggaccctcagat	Ministry of Public
Public Health,		P- caactggcagtaacca	Health, Thailand ,
Thailand		R- ccccactgcgttctccatt	2019-nCoV

Table 3: Fragment 2

Assay	Assay	Primer and Probe Sequences	Alternate assay
Developer	Name		names
Centers for	China	F- ccctgtgggttttacacttaa	Centers for
Disease	ORF1ab	P- ccgtctgcggtatgtggaaaggttatgg	Disease Control,
Control, China		R- acgattgtgcatcagctga	China, novel
			coronavirus
			Target 1
Pasteur	Pasteur 1	F- atgagcttagtcctgttg	Pasteur Institute,
Institute		P- agatgtcttgtgctgccggta	COVID-19 Target
		R- ctccctttgttgtgttgt	1, IP2
Pasteur	Pasteur 2	F- ggtaactggtatgatttcg	Pasteur Institute,
Institute		P- tcatacaaaccacgccagg	COVID-19 Target
		R- ctggtcaaggttaatatagg	2, IP4
World Health	RdRp	F- gtgaratggtcatgtgtggcgg	World Health
Organization		P- caggtggaacctcatcaggagatgc	Organization, n-
		R- caratgttaaasacactattagcata	CoV RdRp